Spinraza
Generic name: nusinersen
Dosage form: intrathecal injection
Drug class: Miscellaneous uncategorized agents
What is Spinraza?
Spinraza is a type of medication called an antisense oligonucleotide. It is used to treat children and adults with spinal muscular atrophy (SMA), a type of motor neuron disease. It was the first drug to be approved by the US Food and Drug Administration (FDA) for this group of people.
SMA is an inherited disorder that causes skeletal muscle weakness and wasting, which worsens with age. SMA is most commonly caused by mutations in a gene called SMN1 (survival motor neuron 1), which leaves the body without enough functional SMN protein to keep motor neurons healthy and functioning.
A back-up gene called SMN2 also produces SMN protein, but only a small percentage of the protein produced by SMN2 functions properly. This is because when the protein is being made a portion of the gene called exon 7 tends to be skipped over, so the resulting protein isn't supplied with all of the right building blocks of information it needs to function properly.
Spinraza works by fixing the protein produced by SMN2 so that it functions properly. It does this by making sure that the missing piece of information from exon 7 is included.
Spinraza was approved by the FDA in 2016.
What is Spinraza used for?
Spinraza is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.
Important information
Spinraza can cause serious side effects including:
- Increased risk of bleeding. Complications linked to an increased risk of bleeding have been observed after administration of similar medicines. Your healthcare provider will perform blood tests before you start treatment with Spinraza and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.
- Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney. An increased risk of kidney damage has been observed after administration of similar medicines. Your healthcare provider will perform urine testing before you start treatment with Spinraza and before each dose to monitor for signs of this risk.
Related/similar drugs
Evrysdi, Zolgensma, nusinersen, risdiplam, onasemnogene abeparvovec
What should I tell my doctor before receiving Spinraza?
Before you receive Spinraza, tell your healthcare provider about all of your medical conditions, including if you:
- have a bleeding disorder
- have a kidney disorder
How should I receive Spinraza?
- Spinraza will be administered by a qualified healthcare professional in a treatment center.
- Spinraza is injected into the fluid of the spine (intrathecal injection) over 1 to 3 minutes.
- Before you start treatment with Spinraza and before each dose, your doctor will order blood and urine testing to monitor for the potential risks of bleeding complications or kidney damage.
- You will receive 4 initial loading doses of Spinraza. The first 3 doses will be given at 14-day intervals and the 4th dose will be given 30 days after the 3rd dose.
- After your 4 loading doses, you will receive a maintenance dose of Spinraza every 4 months (3 times per year).
What happens if I miss a dose?
- If a loading dose of Spinraza is delayed or missed, administer it as soon as possible, with at least 14-days between doses and continue dosing as prescribed.
- If a maintenance dose of Spinraza is delayed or missed, administer it as soon as possible and continue dosing every 4 months.
Dosing information
- The recommended dosage of Spinraza is 12 mg (5 mL) per administration
- Spinraza treatment should be initiated with 4 loading doses. The first 3 loading doses should be administered at 14-day intervals. The 4th loading dose should be administered 30 days after the 3rd dose.
- A maintenance dose of Spinraza should be administered once every 4 months thereafter.
- See the full prescribing information for further dosing information.
What are the side effects of Spinraza?
Spinraza may cause serious side effects including:
- Thromocytopenia and coagulation abnormalities
- Renal toxicity
The most common side effects of Spinraza include:
- lower respiratory infection
- fever, constipation
- headache
- vomiting
- back pain
- post-lumbar puncture syndrome
These are not all of the possible side effects of Spinraza. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Interactions
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
Pregnancy and breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before taking Spinraza. Spinraza may cause fetal harm according to the results of studies conducted in animals.
Tell your doctor if you are breastfeeding or plan to breastfeed before taking Spinraza. Talk to your doctor about the best way to feed your baby while receiving treatment with Spinraza.
Storage
- Store Spinraza in a refrigerator between 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
- Do not freeze.
- Spinraza should be protected from light and kept in the original carton until time of use.
- If no refrigeration is available, Spinraza may be stored in its original carton, protected from light at or below 30°C (86°F) for up to 14 days.
- Prior to administration, unopened vials of Spinraza can be removed from and returned to the refrigerator, if necessary. If removed from the original carton, the total combined time out of refrigeration should not exceed 30 hours at a temperature that does not exceed 25°C (77°F).
Keep out of reach of children.
What are the ingredients in Spinraza?
Active ingredient: nusinersen
Inactive ingredients: monobasic dihydrate sodium phosphate, dibasic anhydrous sodium phosphate, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, water
Spinraza is manufactured by Biogen, Cambridge, MA 02142.
Popular FAQ
The Spinraza mechanism of action involves altering the splicing of the SMN2 gene to increase the levels of a more functional SMN protein. Spinraza is used to treat spinal muscular atrophy (SMA), a decline in muscle strength over time, in adults and children. People with SMA have a mutated SMN1 gene and can’t generate enough SMN protein needed for muscle development and strength.
Zolgensma (onasemnogene abeparvovec-xioi) and Spinraza (nusinersen sodium) are both treatments for people with spinal muscular atrophy (SMA). There are a number of key differences between the two treatments, including:
- Which patients with SMA they are approved for use in
- How often they are administered
- The type of treatments they are
- How they work
- How well they work
Evrysdi (risdiplam) and Spinraza (nusinersen) work in different ways to increase the level of functional SMN (survival of motor neuron) protein in people with spinal muscular atrophy (SMA). A key difference between the two drugs is that Evrysdi is taken orally, whereas Spinraza needs to be given via intrathecal injection. Continue reading
Spinraza (nusinersen) is injected using a syringe directly into the cerebrospinal fluid (CSF), the fluid around the spine, over 1-3 minutes. This type of injection is called an intrathecal bolus injection. Continue reading
References
More about Spinraza (nusinersen)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous uncategorized agents
- En español
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
